US Bancorp’s KalVista Pharmaceuticals KALV Stock Holding History

US Bancorp’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-708	Closed	-$14.3K	–	4269
2026 Q1	$14.3K	Sell	708 -2	-0.3%	-$32	﹤0.01%	3238
2025 Q4	$11.5K	Buy	710 +63	+10%	+$834	﹤0.01%	3288
2025 Q3	$7.88K	Buy	647 +114	+21%	+$1.57K	﹤0.01%	3391
2025 Q2	$6.03K	Sell	533 -37	-6%	-$452	﹤0.01%	3582
2025 Q1	$6.58K	Buy	+570	New	+$5.82K	﹤0.01%	3573
2022 Q4	–	Sell	-2,984	Closed	-$43K	–	4217
2022 Q3	$43K	Buy	+2,984	New	+$41.7K	﹤0.01%	2630
2021 Q3	–	Sell	-113	Closed	-$3K	–	4131
2021 Q2	$3K	Buy	+113	New	+$2.96K	﹤0.01%	3733

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

US Bancorp's KALV Position: Q2 2026 in Review

US Bancorp sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 708 shares — an estimated $14.3K sold.

US Bancorp first reported a position in KALV in Q2 2021 and held it in 7 quarters. The position peaked at $43K in Q3 2022. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

US Bancorp reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 708 KalVista Pharmaceuticals shares in Q2 2026, an estimated $14.3K.
US Bancorp first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 7 quarters.
US Bancorp's KalVista Pharmaceuticals position peaked at $43K in Q3 2022.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.